5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2018
- GMDHC1666TDB
- Pages: 63
- September 2018
- Region : Global
- Global Markets Direct
- Market Research Report
- Details
- Table Of Content
- Licence Rights
- Section Purchase
- Products and Companies
Details
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Pipeline Review, H2 2018
Summary
According to the recently published report '5-Hydroxytryptamine Receptor 6-Pipeline Review, H2 2018'; 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic and cholinergic neurotransmission in brain, whereas activation enhances GABAergic signaling in a widespread manner. Antagonism of 5-HT6 receptors facilitates dopamine and norepinephrine release in the frontal cortex while stimulation has the opposite effect. 5-HT6 receptor plays an important role in Alzheimer's disease and other forms of dementia and obesity.
The report '5-Hydroxytryptamine Receptor 6-Pipeline Review, H2 2018' outlays comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders, Respiratory and Undisclosed which include indications Psychiatric Disorders, Schizophrenia, Alzheimer's Disease, Anxiety Disorders, Cognitive Disorders, Dementia, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Bipolar Disorder (Manic Depression), Dementia Associated With Alzheimer's Disease, Depression, Idiopathic Pulmonary Fibrosis, Major Depressive Disorder, Neurology, Obesity, Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder and Unspecified.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
- The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table Of Content
Scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Overview
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Companies Involved in Therapeutics Development
Acorda Therapeutics Inc
Adamed Sp z oo
Avineuro Pharmaceuticals Inc
Celon Pharma SA
H. Lundbeck AS
Reviva Pharmaceuticals Inc
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Drug Profiles
ADN-1184-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-2013-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-3662-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-3208-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-101-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-211-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-3205-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-322-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-492-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HEC-30654AcOH-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
landipirdine-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LuAF-35700-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-5063-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-502-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Dormant Products
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Discontinued Products
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)-Product Development Milestones
Featured News & Press Releases
Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101
Nov 13, 2017: Suven Life sciences announces presentation on its cognitive disorders drug candidate SUVN-502 at Neuroscience 2017 at Washington DC
Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension
Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016
Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia
Dec 07, 2015: Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer's Disease
Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits
Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist
Dec 23, 2014: Biotie Announces Start Of Syn120 Phase 2A Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events
Dec 14, 2014: AllaChem Completes Phase Ib/IIa Clinical Study with AV4025, an HCV NS5A Inhibitor
Sep 08, 2014: Suven Life Sciences Provides Update On Its Molecule For Alzheimer's Disease
Jul 30, 2014: Biotie updates outlook on SYN120
Jul 16, 2014: Biotie Therapies Selects Bracket's CDR System for Phase 2 Trial of Treatment of Parkinson's disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Figure
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
List Of Table
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Acorda Therapeutics Inc, H2 2018
Pipeline by Adamed Sp z oo, H2 2018
Pipeline by Avineuro Pharmaceuticals Inc, H2 2018
Pipeline by Celon Pharma SA, H2 2018
Pipeline by H. Lundbeck AS, H2 2018
Pipeline by Reviva Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Dormant Products, H2 2018 (Contd..3), H2 2018
Discontinued Products, H2 2018
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
Products and Companies
Products
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Therapeutic Products under Development, Key Players in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Therapeutics, 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Pipeline Overview, 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Pipeline, 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Pipeline Assessment
Companies
Acorda Therapeutics Inc
Adamed Sp z oo
Avineuro Pharmaceuticals Inc
Celon Pharma SA
H. Lundbeck AS
Reviva Pharmaceuticals Inc
Related Reports
Page 130 | 
May 2019
Page 155 | April 2019
Page 159 | March 2019
Page 222 | January 2019
Page 93 | December 2018